Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00087
|
|||||
| Drug Name |
Cladribine
|
|||||
| Synonyms |
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine; Adenosine, 2-chloro-2'-deoxy; CL9; Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribine (JAN/USAN/INN); Cladribine [USAN:INN:BAN]; Cladribinum; CldAdo; Leustat; Leustatin; Leustatin (TN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Litak; Movectro;Mylinax; RWJ 26251; RWJ-26251; RWJ-26251-000
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hairy cell leukemia [ICD11: 2A82.2] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H12ClN5O3
|
|||||
| Canonical SMILES |
C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
|
|||||
| InChI |
InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
|
|||||
| InChIKey |
PTOAARAWEBMLNO-KVQBGUIXSA-N
|
|||||
| CAS Number |
CAS 4291-63-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 285.69 | Topological Polar Surface Area | 119 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
0.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103602769
, 104350170
, 118046705
, 124659094
, 124757075
, 124800053
, 124886798
, 124886799
, 125163879
, 126624559
, 126655830
, 128966217
, 131314655
, 134337856
, 134984314
, 135683425
, 14799875
, 14897807
, 26719669
, 26757803
, 29287787
, 46386544
, 46504588
, 48415788
, 49865077
, 49903916
, 49903918
, 50104045
, 50446026
, 56312468
, 56312469
, 56312470
, 56312853
, 56422184
, 57309572
, 57330593
, 610461
, 71821359
, 7848433
, 7978577
, 7978957
, 8165006
, 855756
, 866156
, 87323981
, 92308638
, 92713835
, 99218181
, 99431527
, 99437023
|
|||||
| ChEBI ID |
CHEBI:567361
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| ENT3 | Transporter Info | Equilibrative nucleoside transporter 3 | Substrate | [3] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [4] | ||
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | ENT3 | Transporter Info | Km = 1860 microM | Xenopus Oocytes-ENT3 | [3] | |
| References | ||||||
| 1 | Cladribine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. | |||||
| 3 | Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.